Remember
plan coding requirements vary.
Plan coding requirements
may vary, so it is important to check with each plan as
to plan-specific requirements. For claim
submission procedures regarding government programs (eg, Medicaid),
contact the appropriate program representative.
This resource
is not intended to be conclusive or exhaustive as to what
codes may be appropriate. You are solely responsible
for determining the appropriate codes. Diagnosis codes should
be selected only by a health care professional. Consult the
ICD-9-CM 2008 manual to check the appropriateness of a particular
code and for information on additional codes. Merck does not
warrant or guarantee the timeliness or appropriateness of this
information for your particular use and cannot guarantee that
use of this information will result in reimbursement. Merck
is not responsible for any action you take in billing for a
Merck vaccine.
CPT codes are used for billing professional services.
Note that CPT 90472 (listed above) is expected to apply when
more
than 1 vaccine is administered the same day.
ICD-9-CM codes
may be utilized or mandated by payers to describe the viral
disease for which the prophylactic vaccination is
administered. There is not currently an ICD-9-CM code specific
to the HPV vaccine. (This resource reflects information available
to Merck as of January 2008.)
For additional information regarding
CPT product and administration codes, and ICD-9-CM codes
concerning GARDASIL, go to the Merck
Vaccine Reimbursement Support Center through www.vaccinesupportservices.com.
GARDASIL
is a vaccine indicated in girls and women 9 to 26 years of
age for the prevention of cervical cancer, precancerous
or dysplastic lesions, and genital warts caused by HPV Types
6, 11, 16, and 18.
> Learn how to help
protect girls and young women.
Select Safety Information
GARDASIL is contraindicated in individuals with hypersensitivity, including
severe allergic reactions to yeast, or after a previous dose of GARDASIL.
GARDASIL does not substitute for routine cervical cancer screening, and women
who receive GARDASIL should continue to undergo screening.
GARDASIL is not recommended for use in pregnant women.
GARDASIL has not been demonstrated to provide protection against diseases
from vaccine and non-vaccine HPV types to which a woman has
previously been exposed through sexual activity.
GARDASIL is not intended to be used for treatment of active genital warts;
cervical cancer; cervical intraepithelial neoplasia, vulvar intraepithelial
neoplasia, or vaginal intraepithelial neoplasia.
GARDASIL has not been shown to protect against diseases due to HPV types not
contained in the vaccine.
The most common adverse reaction was headache. Common adverse reactions that
were observed among recipients of GARDASIL at a frequency of at least 1.0%
and greater than placebo were fever, nausea, dizziness; and injection-site
pain, swelling, erythema, pruritus, and bruising.
In addition, syncope has been reported following vaccination with GARDASIL,
sometimes resulting in falling with injury. Observation for 15 minutes after
administration is recommended.
GARDASIL should be administered in 3 separate intramuscular injections in
the deltoid region of the upper arm or in the higher anterolateral area of
the thigh over a 6-month period with the first dose at an elected date, the
second dose 2 months after the first dose, and the third dose 6 months after
the first dose.
Before administering GARDASIL, please read the Prescribing
Information and Patient
Product Information.
|
